Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Journal of Geriatric Oncology|June 5, 2014
Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipientsJesse W Keller, Charalambos Andreadis, Lloyd E Damon, et al.
Biorxiv : the Preprint Server for Biology|July 15, 2025
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid LeukemiaBogdan Popescu, Matthew F Jones, Madison Piao, et al.
Leukemia & Lymphoma|October 23, 2015
Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remissionGabriel N Mannis, Thomas G Martin, Lloyd E Damon, et al.
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Nature|April 17, 2012
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaCatherine C Smith, Qi Wang, Chen-Shan Chin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2022
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, Alexander E Perl, Joseph Maly, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 9, 2021
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid LeukemiaCatherine C Smith, Aaron D Viny, Evan Massi, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk StratificationCheryl A C Peretz, Vanessa E Kennedy, Anushka Walia, et al.
Cell Reports. Medicine|November 22, 2023
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AMLBogdan Popescu, Carlos Stahlhut, Theodore C Tarver, et al.
Pageof 8